SHINE Technologies Secures $240 Million Funding with Dr. Patrick Soon-Shiong Joining Its Board

SHINE Technologies Secures Major Investment in Nuclear Fusion

In a significant milestone in the realm of clean energy technologies, SHINE Technologies – a leader in nuclear fusion development – has announced that it has successfully raised $240 million in equity funding. The investment round was notably led by NantWorks, spearheaded by renowned physician and entrepreneur Dr. Patrick Soon-Shiong, who has consequently joined SHINE's Board of Directors. This funding marks a new chapter in SHINE’s journey towards revolutionizing energy production and medical solutions through advanced fusion technology.

Investment and Strategic Vision

SHINE’s latest funding round witnessed participation from several prominent investors, including Fidelity Management & Research Company, Sumitomo Corporation of Americas, Pelican Energy Partners, Deerfield Management, and Oaktree Capital Management among others. The financial backing is set to enhance SHINE’s existing portfolio, which encompasses crucial neutron testing services and the production of radioisotopes used in cutting-edge cancer therapies and diagnostic imaging.

Greg Piefer, the CEO and founder of SHINE, expressed his excitement about the new partnership, emphasizing the revolutionary potential of fusion energy. He stated, “Fusion energy is one of the most important technologies humanity will ever develop — it will forever change how we power our species and is already having a substantial impact across advanced manufacturing, healthcare, and recycling.” He regards Dr. Soon-Shiong as a progressive figure whose work aligns well with SHINE’s mission to leverage breakthrough science for societal benefits.

Dr. Patrick Soon-Shiong's Impact

Dr. Soon-Shiong, known for establishing two major pharmaceutical companies and his commitment to transforming cancer care, brings immense experience to SHINE. His past ventures include the development of numerous FDA-approved therapies. He emphasized that the partnership focuses on innovative science aimed at enhancing human health. His insights into Lu-177-based therapies, which target cancer cells with precision, align with SHINE’s vision of expanding therapeutic technologies to cover a broader range of oncological needs.

“I’m honored to join SHINE’s Board as we translate breakthrough science into real-world impact for patients and society,” Dr. Soon-Shiong remarked. He specifically points out that Lu-177 holds promise for future expansion in cancer treatment, thus aligning well with SHINE’s objectives.

The Road Ahead

With this investment, SHINE aims to further develop technologies focused on recycling used nuclear fuel, paving the way for a sustainable future in nuclear energy. This initiative reflects SHINE's commitment to transforming traditional energy paradigms by enhancing the viability of fusion energy on a commercial scale.

SHINE has now amassed over $1 billion total in funding since its inception, showcasing consistent investor confidence in its vision to advance nuclear fusion and related technologies. The company not only seeks to innovate within the energy sector but also plans to propagate developments that contribute to healthcare, establishing itself as a multi-faceted leader in the industry.

About SHINE Technologies

Headquartered in Janesville, Wisconsin, SHINE Technologies is at the forefront of developing fusion technologies that prioritize safety, efficiency, and environmental sustainability. The firm successfully commercializes fusion in various applications, including neutron testing markets and the production of critical medical isotopes vital for diagnosing and treating conditions such as heart disease and cancer.

Their advances have positioned them as one of the largest Lu-177 production facilities in North America, with an annual production capacity reaching up to 100,000 doses, potentially scaling to 200,000. SHINE has maintained an impressive record, achieving over 95% on-time delivery since launching their iliumira products in 2024, validating their commitment to excellence and reliability in the healthcare supply chain.

As SHINE continues to venture forward in both the energy and healthcare sectors, it remains committed to addressing the challenges posed by traditional energy methods and healthcare needs, ultimately driving forward revolutionary technologies that promise a sustainable future for all.